Oral sunitinib malate (Sutent) is a tyrosine kinase inhibitor that prevents binding of vascular endothelial growth factor and platelet-derived growth factor to their native receptors.1 It has been approved by the US Food and Drug Administration for the treatment of renal cell carcinoma (RCC) and imatinib mesylate–resistant gastrointestinal stromal tumor. Choroidal metastasis from RCC is rare, composing only 3% of all choroidal metastases.2 Herein, we report the first case, to our knowledge, of rapid involution of choroidal metastasis secondary to RCC using sunitinib.
Chin EK, Almeida DRP, Sacher BA, Boldt HC. Rapid Involution of Choroidal Metastasis Secondary to Renal Cell Carcinoma With Oral Sunitinib. JAMA Ophthalmol. 2015;133(1):109-110. doi:10.1001/jamaophthalmol.2014.3931